Pharmaceutical laboratory and equipment provider Sartoriushttp://www.sartorius.com, has acquired U.S.-based IntelliCyt Corporation, a manufacturer of novel cell screening platforms used in drug discovery. Through the acquisition, Sartorius expands its current lab portfolio into bio analytics, strengthening its offering for biopharma customers and academia.

Sartorius purchased IntelliCyt for $90 million. The company focuses on pharma, biotech and academic customers, and achieved strong double-digit annual growth during the past few years. Based in Albuquerque, NM, IntelliCyt employs 55 people and is expected to generate sales revenues of more than $18 million in 2016 (2015: $13.4 million).

“Novel cell screening methods are crucial to enable scientific progress in the fast-expanding research areas of immuno-oncology, antibody discovery and immune targets. IntelliCyt has developed a powerful platform that integrates instruments, reagents and software seamlessly across the workflow. This is a great addition to our laboratory products portfolio,” said Joachim Kreuzburg, chief executive officer, Sartorius.

Terry Dunlay, founder, president and chief executive officer, IntelliCyt, said, “By coupling the global market presence and strong infrastructure of Sartorius with IntelliCyt’s enabling cell analysis platform, we will be better able to deliver value to our customers, further penetrate our core markets, and grow the business to the next level.”